By Nigam Arora
Pullback Is Opportunity
Boston Scientific (BSX) has built one of the strongest franchises in the global medical device industry. Through disciplined innovation and targeted strategic expansion, the company has consistently strengthened its position in fast growing therapeutic categories. The pullback in BSX is a buying opportunity for the long term investor.
Reason For Pullback
The pullback in BSX is the direct result of the company’s acquisition of Penumbra (PEN).
Markets frequently react negatively when a major acquisition is announced or completed. The reason is simple: acquisitions are dilutive in the short term.
When a large company buys another company:
-
Financing costs impact earnings
-
Integration expenses temporarily pressure margins
-
Accounting treatment reduces near term earnings per share
The market focuses on these short term effects. This reaction misses the bigger point.
The purpose of the Penumbra acquisition is to expand Boston Scientific’s presence in high-growth procedural categories that will generate substantial revenue and earnings expansion over time.
Short term dilution is the price paid for long term growth.
Penumbra
Penumbra built one of the leading technology platforms in thrombectomy and neurovascular intervention. These technologies are used to remove blood clots and restore blood flow in conditions such as stroke and vascular blockages.
These procedures are expanding rapidly because:
-
Physicians are intervening earlier
-
Technology has improved dramatically
-
Hospitals are increasingly adopting minimally invasive approaches
By integrating Penumbra’s technology and physician relationships, Boston Scientific significantly strengthens its position in a high-growth segment of interventional medicine.
This type of strategic expansion is exactly how leading medical device companies build durable growth platforms.
Aging Population
The most powerful long term driver in the medical device sector is demographics.
Populations across developed economies are aging rapidly. As populations age, the incidence of stroke, cardiovascular disease, and vascular conditions rises sharply.
That drives sustained demand for devices used in:
-
Stroke treatment
-
Vascular intervention
-
Cardiac procedures
-
Structural heart therapies
Boston Scientific sits directly at the center of these trends.
As the global population ages, procedure volumes increase. Companies with strong device portfolios benefit directly from that growth.
Core Position
The core BSX position is in the ZYX Buy Core Model Portfolio.
Trade Around Position
There is also a trade around position on BSX. There is a separate post regarding the trade around position.
Those starting a core position now should consider not starting a trade around position now.
Trade around positions are a technique used by billionaires and hedge funds to dramatically increase returns and reduce risk. Please see the Trade Management for Guidelines for more on trade around positions.
Core Position Zones
For those who are following the Good Way, the Buy Now rating is *** (To see the locked content, please take a 30 day free trial) to scale in.
For those following the Best Way, the buy zone is $*** – $*** to scale in.
To learn about the Good Way and Best Way, please see the Getting A Running Start Guide. To learn about zones, full core position size, and scaling in, please see the Trade Management Guidelines.
The recommended quantity is ***% – ***% of the full core position size. For those starting a new position now, consider limiting the quantity to ***% – ***% at this time due to unsettled market conditions.
This is a very long term position.
The very long term target is $178 – $186.
What To Do Now
Those in BSX stock may consider continuing to hold. Those not in BSX stock may consider following the parameters given above.
Note: Signal(s) to enter, add, reduce, exit, hold or change.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
